Pharmaceutical composition and preparation method thereof

A composition and drug technology, applied in the field of pharmaceutical compositions, can solve the problems of complex process operation, high production cost, uneven drug application, etc., and achieve the effect of simple process operation, low production cost and improved storage stability

Active Publication Date: 2017-07-07
SHENZHEN PHARMACIN CO LTD
View PDF2 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The process applies the drug by fluidizing the surface of the organic acid core material, that is, the drug is formulated into a suspension for drug application. This process has the advantages of low drug application rate, large drug loss, uneven drug application, and uncertain drug dosage. The process operation is complex and other disadvantages, and the degree of sphericity of the prepared organic acid pellet core, the degree of perfection of the coating film of the separation layer, and the degree of combination of the active drug and the separation layer need to be strictly controlled, so the production cost is high and the production cycle is long.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical composition and preparation method thereof
  • Pharmaceutical composition and preparation method thereof
  • Pharmaceutical composition and preparation method thereof

Examples

Experimental program
Comparison scheme
Effect test

no. 1 example

[0039] recipe one

[0040]

[0041] Control group formula:

[0042] Dabigatran etexilate mesylate 173.0mg

[0043] Tartaric acid 177mg

[0044] Total 350mg

[0045] Dabigatran etexilate mesylate, tartaric acid, and sodium carbonate are all commercially available raw materials.

[0046] According to formula 1, dissolve a certain amount of sodium carbonate in 20mL of water, add tartaric acid powder particles with a particle size of 0.4-1.5mm to the aqueous solution of sodium carbonate under stirring, and mix the tartaric acid powder particles Put into drying equipment such as a drying box or a fluidized bed to dry to obtain modified tartaric acid powder particles.

[0047] The modified tartaric acid powder granules and the dabigatran etexilate mesylate in the formula one are mixed uniformly and packed into hydroxypropyl methylcellulose (HPMC) capsules, and the capsules are packed into high-density polyethylene (HDPE) bottles , HDPE built-in desiccant, after storage for 1...

no. 2 example

[0053] recipe two

[0054]

[0055] According to formula 2, dissolve a certain amount of sodium carbonate in 20mL of water, add tartaric acid powder particles with a particle size of 0.4-1.5mm to the aqueous solution of sodium carbonate under stirring, and mix the tartaric acid powder particles Put into drying equipment such as a drying box or a fluidized bed to dry to obtain modified tartaric acid powder particles.

[0056] Then dabigatran etexilate mesylate is mixed with the above-mentioned modified tartaric acid powder particles, further mixed with other pharmaceutical excipients, and packed into HPMC capsules to make a pharmaceutical preparation product.

no. 3 example

[0058] The dabigatran etexilate mesylate is mixed with modified tartaric acid powder particles, further mixed with other pharmaceutical excipients, and packed into HPMC capsules to make a pharmaceutical preparation product. figure 2 Dissolution results of capsules prepared with different ratios of dabigatran etexilate mesylate API and modified tartaric acid. Dissolution uses the basket method specified in the Pharmacopoeia at 100 rpm, the solvent is water, and the temperature is 37°C.

[0059] The results show that the dissolution of the dabigatran etexilate mesylate preparation product after adding the modified tartaric acid is significantly improved than the dissolution of the preparation without adding the modified tartaric acid.

[0060] To sum up, the pharmaceutical composition of the present invention has excellent storage stability, obtains high solubility, and provides expected bioavailability. At the same time, the method for modifying the surface of the pharmaceuti...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
solubility (mass)aaaaaaaaaa
particle diameteraaaaaaaaaa
Login to view more

Abstract

The invention relates to a pharmaceutical composition for oral administration, a preparation method and an application of the pharmaceutical composition as well as a modifying method of acid pharmaceutical adjuvants, wherein the pharmaceutical composition consists of a) the pharmaceutically acceptable surface-modified acid pharmaceutical adjuvants, and b) dabigatran etexilate, or pharmaceutically acceptable salt or a hydrate; and the modifying method comprises the following steps: preparing a pharmaceutically acceptable modifying alkaline substance water solution, and adding the water solution to powder particles of the acid pharmaceutical adjuvants, so that a neutral salt layer is each formed on the surface of the powder particles of the acid pharmaceutical adjuvants, so that hydrotropy can be performed by virtue of the acid adjuvants in a preparation prescription of the dabigatran etexilate, and meanwhile, the dabigatran etexilate can be prevented from being broken up by the acid adjuvants. The technology is also applicable to surface modification of alkaline pharmaceutical adjuvants, so that a neutral salt layer is each formed on the surfaces of the alkaline pharmaceutical adjuvants; therefore, the alkaline pharmaceutical adjuvants are prevented from being broken up by pharmaceutical active ingredients.

Description

technical field [0001] The invention relates to a pharmaceutical composition, which contains a pharmaceutically acceptable surface-modified acidic pharmaceutical auxiliary material. Particularly, the present invention relates to a kind of pharmaceutical composition, and it contains dabigatran etexilate (active substance) or its pharmaceutically acceptable salt, hydrate and pharmaceutically acceptable surface-modified acidic pharmaceutical excipients. Background technique [0002] Many drugs will chemically react with acidic or alkaline materials, which will cause the chemical degradation of the drug. Under normal circumstances, these acidic or alkaline materials will be avoided as far as possible in the preparation products of these drugs that are decomposed by acid or alkali. However, in some special cases, these unstable drugs may require some acidic or alkaline materials, so that the preparation products of these drugs meet certain requirements. [0003] One example is ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/4439A61K47/12A61K9/48A61P7/02
CPCA61K9/4816A61K9/4858A61K31/4439
Inventor 王泽人赵玉兰王立江张晓
Owner SHENZHEN PHARMACIN CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products